Partnership website: https://www.innoenergy.com/
The primary focus is to create sustainable energy solutions in all aspects of production, through enhancing collaboration among the three pillars of the knowledge triangle and fostering innovation that can be embraced by the market.
EIT InnoEnergy concentrates on the following thematic fields:
If you are an innovator with a promising technology or service aligned with any of these eight thematic fields, you can apply to join the ecosystem. Among other benefits, joining the ecosystem allows exposure and access to the venture capital community.
EIT InnoEnergy not only provides funding possibilities, but also assists in making your product or service market-ready, transforming it into a viable business.
Additionally, EIT InnoEnergy has an education pillar focused on training workers who will operate in these innovative areas, called InnoEnergy Skills Institute.
With the e-mobility future in mind, EIT InnoEnergy partnered with European Battery Alliance to establish an upskill and reskill programme: EBA Academy.
There are regular announcements for calls for proposals for different programs (EIT, EIC, third party calls for proposals, ...). To explore the opportunities and stay updated with the latest news, please visit the innovation community's webpage.
The EIT InnoEnergy community has several regional innovation hubs, including one based in Genk. If you wish to contact them, you can reach out via email at benelux@innoenergy.com.
The annual EIT conference, InnoveEIT, is an opportunity to connect with other community members and learn from EIT experts. You can watch the recording of the 2022 edition on the official webpage.
Finally, for any inquiries related to energy, you can contact the National Contact Point (NCP) at ria.debreucker@vlaio.be.
Partnerships group the EC and private and/or public partners, to coordinate and streamline the research & innovation initiatives and funding in some selected key domains.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.